Medisafe Partners with Merck KGaA, Darmstadt, Germany to Improve Adherence for Patients with Cardiometabolic Disorders in Russia, Mexico and Brazil

BOSTON/PRNewswire/ -- Medisafe, the leading medication management platform with over four and a half million registered users, announced today a further step in its collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The initiative, which is supporting medication adherence and engagement for patients taking Merck KGaA, Darmstadt, Germany's cardiometabolic medications has now been launched in Brazil, Mexico and Russia.

Together Medisafe and Merck KGaA, Darmstadt, Germany are providing patients access to a version of Medisafe, with targeted content, interventions and additional features to supplement Medisafe's personalized medication adherence platform.

The cooperation was first announced by Merck KGaA, Darmstadt, Germany in March 2018.  Since then, Medisafe has been working hand in hand with the local Merck KGaA, Darmstadt, Germany teams on the release of the localized versions of Medisafe, tailored to fit the unique needs of each country's patients. 

"About 66 million patients around the world rely on our medicines for cardiometabolic disorders. Unfortunately, we know that often patients don't take their medication in full accordance with the treatment regimen prescribed by their healthcare professional. With Medisafe, we would like to help patients with chronic conditions to better organize their medication, therefore improve adherence to their regimen and ultimately achieve the best possible treatment outcomes," said Leif Moll, Head of General Medicine Strategy & Portfolio Expansion, at the biopharma business of Merck KGaA, Darmstadt, Germany.

The global adherence rate hovers around 50% and can be considerably lower in developing nations where adherence rates are more difficult to track1. Nonadherence to medication may lead to a range of avoidable comorbidities, hospitalizations and medical events, as well as a loss of economic productivity when patients are unable to work. The collaboration between Medisafe and Merck KGaA, Darmstadt, Germany is designed to combat these issues by providing a digital solution for patients with Type 2 Diabetes, thyroid disorders, and cardiovascular issues.

The collaboration will also offer Merck KGaA, Darmstadt, Germany the opportunity to reveal new insights into patient behavior trends through aggregated, de-identified data on the Medisafe platform. These insights may contribute to improved management of chronic disease in the future. 

"We are pleased to work with Merck KGaA, Darmstadt, Germany, a leading organization aligned with Medisafe's values of putting patients first and supporting innovative digital solutions for improving adherence," said Omri Shor, CEO of Medisafe. "Patients can face tremendous challenges in managing their medications and Medisafe is excited to provide the premier personalized solution to combat nonadherence."

About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.



  1. World Health Organization Adherence to Long-Term Therapies, Evidence for Action, 2013

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.


Medisafe is a leading medication management and adherence solution in which M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, has invested in. Medisafe's  over 4.5 million registered patient and caregiver users who have recorded over one billion successful medication doses on their iOS and Android smartphones and tablets and contributed 180,000 user reviews that average 4.6 out of 5 stars in the App Store and Google Play app stores. Medisafe's cloud-based mobile platform personalizes content, resources and interventions — such as educational videos, coupons and motivational messages — based on each user's regimen, condition and specific circumstance. Medisafe fosters collaboration among patients, their loved ones and healthcare professionals through caregiver tools and reports and helps the healthcare professionals improve health outcomes and sustain quality care initiatives. Medisafe is a HIPAA and GDPR compliant solution and ISO 27001:2013 certified. For its innovative product, Medisafe was selected Gartner Cool Vendor in the Life Sciences category in 2018.